icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
Back grey_arrow_rt.gif
MK-8591/Islatravir vs ART Resistance / Metabolics
  Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection.....
Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP....http://www.natap.org/2019/IAS/IAS_67.htm
MK-8591 Potency and PK Provide High
Inhibitory Quotients at Low Doses QD and QW
Common NRTI mutations, including M184I/V, thymidine analog mutations, K65R, and K70E, confer low fold-shifts in antiviral potency, and MK-8591 retains greater IQs against these NRTI-resistant viruses than those of TDF, TAF, and 3TC with WT virus.